| High | $19.00 |
|---|---|
| Median | $15.00 |
| Low | $12.00 |
| Average | $15.40 |
| Current Price | $6.94 |
Is Aveo a good stock to buy?
AVEO Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Will AVEO go Up?
Aveo Pharmaceuticals Inc (NASDAQ:AVEO) The 5 analysts offering 12-month price forecasts for Aveo Pharmaceuticals Inc have a median target of 15.00, with a high estimate of 19.00 and a low estimate of 12.00. The median estimate represents a +115.83% increase from the last price of 6.95.
How much does a Aveo car cost?
MakeAvg PriceYoYCarGurus Index$30,925+11.08%Chevrolet Aveo$5,966+17.06%2005 Chevrolet Aveo$4,958+21.49%2007 Chevrolet Aveo$4,964+6.36%3 more rows
What is the price of Chevrolet Aveo in India?
Chevrolet Aveo LT 1.4 Key SpecificationsPrice₹ 6.90 LakhMileage (ARAI)14.49 kmplEngine1399 ccTransmissionManualFuel TypePetrol1 more row
What is AVEO Pharmaceuticals's consensus rating and price target?
According to the issued ratings of 3 analysts in the last year, the consensus rating for AVEO Pharmaceuticals stock is Buy based on the current 3 b...
Do Wall Street analysts like AVEO Pharmaceuticals more than its competitors?
Analysts like AVEO Pharmaceuticals stock more than the stock of other Medical companies. The consensus rating score for AVEO Pharmaceuticals is 3.0...
Do MarketBeat users like AVEO Pharmaceuticals more than its competitors?
MarketBeat users like AVEO Pharmaceuticals stock more than the stock of other Medical companies. 67.45% of MarketBeat users gave AVEO Pharmaceutica...
Does AVEO Pharmaceuticals's stock price have much upside?
According to analysts, AVEO Pharmaceuticals's stock has a predicted upside of 173.47% based on their 12-month price targets.
What analysts cover AVEO Pharmaceuticals?
AVEO Pharmaceuticals has been rated by Jonestrading in the past 90 days.
What is AVEO’s average 12-month price target, according to analysts?
Based on analyst ratings, AVEO Pharma’s 12-month average price target is $15.75.
What is AVEO’s upside potential, based on the analysts’ average price target?
AVEO Pharma has 264.58% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the [object Object] tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the [object Object] and follow the analysts of your choice. Visit their profiles for more details a...
Stock Price Forecast
Analyst Recommendations
The 4 analysts offering 12-month price forecasts for Aveo Pharmaceuticals Inc have a median target of 16.00, with a high estimate of 19.00 and a low estimate of 15.00. The median estimate represents a +366.47% increase from the last price of 3.43.
What is AVEO oncology?
The current consensus among 4 polled investment analysts is to Buy stock in Aveo Pharmaceuticals Inc. This rating has held steady since November, when it was unchanged from a Buy rating. Move your mouse over past months for detail
When is Aveo earnings call 2021?
AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will host a key opinion leader webinar focusing on ficlatuzumab, the Company’s investigational potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor (HGF), being studied in head and neck squamous cell carcinoma (HNSCC) on Wednesday, June 16 , 2021 at 2:00 p.m. Eastern Time .
How does MarketBeat calculate stock ratings?
NEW YORK, NY / ACCESSWIRE / May 10, 2021 / AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 10, 2021 at 4:30 PM Eastern Time.
Does MarketBeat like AVROBIO?
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
